Figure 8
(a) Western analysis of the effect of the p42/p44 MAPK inhibitor PD98059 (PD) on myocardial p-ERK and GATA-4 expressions. (b and c) Effect of PD, the COX-2 inhibitor NS398 (NS), and AMD3100 (AMD) on DOX-induced cardiomyopathy. Bars are means±s.e.m.; *P<0.05 vs the untreated sham group (DOX (−) and G-CSF (−)); #P<0.05 vs the untreated DOX group (DOX (+) and G-CSF (−)); 
P<0.05 vs the G-CSF-treated DOX group (DOX (+) and G-CSF (+)). (d) Western blot analysis and the densitometries of the effect of NS on myocardial p-ERK and GATA-4 expressions. NS does not affect inhibition of either p-ERK or GATA-4 by DOX. (e) Western analysis and the densitometry of the effect of PD on myocardial COX-2 expression. PD does not restore inhibition of COX-2 by G-CSF.
